Table 2.
Num. markers | Psoriasis | CAD | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IVW | Median | Mode | MR-RAPS | IVW | Median | Mode | MR-RAPS | ||||||||||
OR | P | OR | P | OR | P | OR | P | OR | P | OR | P | OR | P | OR | P | ||
Psoriasis | 184 | — | — | — | — | — | — | — | — | 1.01 | 0.14 | 1.00 | 0.64 | 1.00 | 0.91 | 1.01 | 0.09 |
CAD | 448 | 1.14 | 6.3 × 10−4 | 1.16 | 3.6 × 10−3 | 1.45 | 0.02 | 1.13 | 2.2 × 10−3 | — | — | — | — | — | — | — | — |
BMI | 969 | 1.48 | 1.5 × 10−9 | 1.38 | 1.0 × 10−3 | 1.96 | 0.08 | 1.50 | 2.2 × 10−9 | 1.51 | 5.1 × 10−71 | 1.52 | 1.6 × 10−61 | 1.45 | 2.8 × 10−4 | 1.51 | 1.6 × 10−69 |
WHR | 796 | 1.53 | 1.0 × 10−6 | 1.49 | 4.4 × 10−4 | 1.12 | 0.78 | 1.52 | 3.1 × 10−6 | 1.56 | 4.5 × 10−50 | 1.60 | 5.9 × 10−47 | 1.23 | 0.21 | 1.57 | 3.6 × 10−50 |
T2D | 561 | 1.05 | 0.08 | 1.07 | 0.08 | 0.86 | 0.29 | 1.06 | 0.06 | 1.16 | 1.1 × 10−41 | 1.18 | 1.4 × 10−45 | 1.16 | 4.3 × 10−4 | 1.16 | 3.3 × 10−39 |
HDL | 362 | 1.04 | 0.44 | 0.92 | 0.35 | 1.23 | 0.21 | 1.06 | 0.27 | 0.87 | 6.1 × 10−9 | 0.87 | 1.5 × 10−8 | 0.89 | 0.17 | 0.88 | 9.6 × 10−11 |
LDL | 301 | 1.04 | 0.43 | 0.98 | 0.78 | 0.86 | 0.29 | 1.02 | 0.67 | 1.31 | 7.2 × 10−35 | 1.19 | 2.3 × 10−13 | 1.11 | 0.19 | 1.44 | 3.4 × 10−211 |
TC | 308 | 1.12 | 0.03 | 1.03 | 0.63 | 0.97 | 0.85 | 1.12 | 0.04 | 1.38 | 7.4 × 10−41 | 1.22 | 3.9 × 10−16 | 1.43 | 8.6 × 10−4 | 1.48 | 1.4 × 10−222 |
TG | 353 | 1.07 | 0.16 | 1.01 | 0.87 | 0.84 | 0.34 | 1.06 | 0.22 | 1.21 | 3.6 × 10−20 | 1.16 | 2.7 × 10−10 | 1.15 | 0.02 | 1.21 | 5.8 × 10−24 |
Results significant after Bonferroni adjustment are indicated in bold.
IVW inverse-variance weighted, Num. number of, CAD coronary artery disease, BMI body mass index, WHR waist-hip ratio, T2D type 2 diabetes, HDL high-density lipoprotein, LDL low-density lipoprotein, TC total cholesterol, TG triglycerides, OR odds ratio, p p-value.